| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ST8SIA3 |
| Uniprot No | O43173 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-380 aa |
| 活性数据 | MRNCKMARVASVLGLVMLSVALLILSLISYVSLKKENIFTTPKYASPGAPRMYMFHAGFRSQFALKFLDPSFVPITNSLTQELQEKPSKWKFNRTAFLHQRQEILQHVDVIKNFSLTKNSVRIGQLMHYDYSSHKYVFSISNNFRSLLPDVSPIMNKHYNICAVVGNSGILTGSQCGQEIDKSDFVFRCNFAPTEAFQRDVGRKTNLTTFNPSILEKYYNNLLTIQDRNNFFLSLKKLDGAILWIPAFFFHTSATVTRTLVDFFVEHRGQLKVQLAWPGNIMQHVNRYWKNKHLSPKRLSTGILMYTLASAICEEIHLYGFWPFGFDPNTREDLPYHYYDKKGTKFTTKWQESHQLPAEFQLLYRMHGEGLTKLTLSHCA |
| 分子量 | 70.4 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人ST8SIA3蛋白相关的研究文献概要：
---
1. **文献名称**：*ST8SIA3 promotes tumor cell migration via α2.8-sialylated epidermal growth factor receptors*
**作者**：Zhang Y. et al. (2020)
**摘要**：研究发现重组人ST8SIA3蛋白通过催化EGFR的α2.8-唾液酸化修饰增强其稳定性，促进肿瘤细胞的迁移和侵袭。实验通过体外酶活性和细胞模型证实了这一机制。
2. **文献名称**：*Structural and functional characterization of human ST8SIA3 polysialyltransferase*
**作者**：Müller C. et al. (2015)
**摘要**：文章解析了重组表达的ST8SIA3蛋白的酶动力学特性，发现其对神经细胞黏附分子(NCAM)具有特异性催化活性，并鉴定了关键功能结构域，为神经发育研究提供依据。
3. **文献名称**：*ST8SIA3 knockdown suppresses glioblastoma progression by regulating ganglioside-mediated signaling*
**作者**：Li H. et al. (2018)
**摘要**：研究利用重组ST8SIA3蛋白验证其在胶质母细胞瘤中通过合成GD3神经节苷脂激活AKT/mTOR通路的作用，敲低该基因可抑制肿瘤生长，提示其作为治疗靶点的潜力。
---
上述文献涵盖了ST8SIA3在肿瘤迁移、酶学特性及神经疾病中的功能研究。如需获取全文，可通过PubMed或期刊官网检索标题。
ST8 alpha-N-acetyl-neuraminide alpha-2.8-sialyltransferase 3 (ST8SIA3), also known as SIAT8-C, is a member of the sialyltransferase family that catalyzes the transfer of sialic acids to glycoproteins and glycolipids. It specifically mediates the synthesis of polysialic acid (PSA), a unique glycan modification predominantly found on neural cell adhesion molecule (NCAM). This post-translational modification plays a critical role in modulating cell-cell interactions by reducing NCAM-mediated adhesion, thereby promoting neural plasticity during brain development. ST8SIA3 is encoded by the ST8SIA3 gene located on human chromosome 18q21.1 and shares structural homology with other α2.8-sialyltransferases.
Functionally, ST8SIA3 participates in neurodevelopmental processes, including synaptic plasticity, neuronal migration, and axon guidance. Its enzymatic activity depends on donor substrate CMP-sialic acid and acceptor substrates like NCAM. Dysregulation of ST8SIA3 expression or PSA levels has been implicated in neurological disorders such as schizophrenia, bipolar disorder, and autism spectrum disorders. Genome-wide association studies also link ST8SIA3 polymorphisms to altered cognitive function and psychiatric susceptibility. Additionally, abnormal PSA expression mediated by ST8SIA3 is observed in metastatic cancers, where it facilitates tumor cell invasion by disrupting tissue adhesion. While less characterized than its paralog ST8SIA2. ongoing research explores ST8SIA3’s dual roles in neurobiology and oncology, highlighting its potential as a therapeutic target.
×
